Hormone Therapy (HT) and cancer;Hormontherapie und krebs

Journal fur Gynakologische Endokrinologie

Volumn 19, Issue 3, 2009, Pages 6-10

  Noss, D ^a   Ortmann, O ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; TIBOLONE;

BREAST CARCINOMA; CANCER PATIENT; CANCER RISK; CLIMACTERIUM; CLINICAL TRIAL; COLORECTAL CARCINOMA; GYNECOLOGIC CANCER; HORMONAL THERAPY; HUMAN; OVARY CARCINOMA; POSTMENOPAUSE; REVIEW; TUMOR GROWTH;

EID: 70349904743     PISSN: 19976690     EISSN: 19961553     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Dietel M, Lewis MA, Shapiro S et al. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005; 20: 2052-2060 (Pubitemid 41418488)
2. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350: 1047-59. Erratum: Lancet 1997; 350: 1484.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 17: 321-333
4. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, LaCroix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299: 1036-1045 (Pubitemid 351347060)
5. Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008; 123: 933-941 (Pubitemid 352032424)
6. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008; 107: 427-430 (Pubitemid 351172118)
7. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27. Erratum: Lancet 2003; 362: 1160.
8. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; on behalf of the LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135-146
9. Green PK, Weiss NS, McKnight B et al. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 1996; 7: 575-580 (Pubitemid 26377726)
10. Ortmann O, König K. Hormontherapie im Klimakterium und in der Postmenopause. Deutsches Ärzteblatt 2005; 102: 144-147
11. Hulley S, Furberg C, Barret-Connor E et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66. (Pubitemid 34705519)
12. Beral V, Bull D, Reeves G et al. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543-1551 (Pubitemid 40615403)
13. Doherty JA, Cushing-Haugen KL, Saltzman BS et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007; 197: 139.e1-7
14. Creasman WT, Henderson D, Hinshaw W et al. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986; 67: 326-330 (Pubitemid 16129969)
15. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990; 36: 189-191 (Pubitemid 20061284)
16. Committee on Gynecologic Practice. Hormone replacement therapy in women treated for endometrial cancer. Int J Gynecol Obstet 2001; 73: 283-284
17. International Agency for Research on Cancer. Working Group on the Evaluation of the Carcinogenic Risks to Humans. Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy. IARC Monographs, Vol 91; 2007.
18. Hunt K, Coleman MP. The completeness of cancer registration in follow-up studies - a cautionary note. Br J Cancer 1987; 56: 357-359 (Pubitemid 17158827)
19. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM; Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1739-1748
20. Lancey JV, Brinton LA, Leitzmann MF et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006; 98: 1397-1405
21. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 2007; 13: 453-463 (Pubitemid 47303949)
22. Beral V, Million Women Study Collaborators, Bull D, Green J et al. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703-1710 (Pubitemid 46755369)
23. Eeles RA, Tan S, Wiltshaw E et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 1991; 302: 259-262
24. Mascarenhas C, Lambe M, Bellocco R et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 2006; 119: 2907-2915 (Pubitemid 44846244)
25. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980; 65: 1201-1207
26. Nanda K, Bastian LA, Hasselblad Vet al. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999; 93: 880-888
27. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350: 991-1004. (Pubitemid 38269276)